{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:07:05Z","timestamp":1783044425373,"version":"3.54.6"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 23 2921 Pj"],"award-info":[{"award-number":["CAN 23 2921 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 20 1226 PjF"],"award-info":[{"award-number":["CAN 20 1226 PjF"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40273-024-01438-z","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T18:02:39Z","timestamp":1727373759000},"page":"31-43","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6594-9813","authenticated-orcid":false,"given":"Maddalena","family":"Centanni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Nijhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1258-8297","authenticated-orcid":false,"given":"Mats O.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2979-679X","authenticated-orcid":false,"given":"Lena E.","family":"Friberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"1438_CR1","unstructured":"Rascati K. Essentials of Pharmacoeconomics [Internet]. Wolters Kluwer Health; 2020. https:\/\/books.google.se\/books?id=0pH-DwAAQBAJ."},{"key":"1438_CR2","unstructured":"Nice. The guidelines manual. 2009. p. 147."},{"key":"1438_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/hec.1093","volume":"15","author":"MJ Sculpher","year":"2006","unstructured":"Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making? Health Econ. 2006;15:677\u201387. https:\/\/doi.org\/10.1002\/hec.1093.","journal-title":"Health Econ"},{"key":"1438_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jval.2015.02.001","volume":"18","author":"SD Ramsey","year":"2015","unstructured":"Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2015;18:161\u201372.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res."},{"key":"1438_CR5","doi-asserted-by":"crossref","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value Health. 2012;15:796\u2013803. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S109830151201652X.","DOI":"10.1016\/j.jval.2012.06.012"},{"key":"1438_CR6","doi-asserted-by":"crossref","unstructured":"Chabot I, LeLorier J, Blackstein ME. The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: The example of sunitinib for gastrointestinal stromal tumour. Eur J Cancer. 2008;44:972\u20137. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0959804908001731.","DOI":"10.1016\/j.ejca.2008.02.041"},{"issue":"Suppl 2","key":"1438_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3310\/hta13Suppl2-10","volume":"13","author":"M Bond","year":"2009","unstructured":"Bond M, Hoyle M, Moxham T, Napier M, Anderson R. Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer. Health Technol Assess. 2009;13(Suppl 2):69\u201374.","journal-title":"Health Technol Assess"},{"key":"1438_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1365-2710.2009.01135.x","volume":"35","author":"L Paz-Ares","year":"2010","unstructured":"Paz-Ares L, Del Muro JG, Grande E, D\u00edaz S. A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System. J Clin Pharm Ther. 2010;35:429\u201338. https:\/\/doi.org\/10.1111\/j.1365-2710.2009.01135.x.","journal-title":"J Clin Pharm Ther"},{"key":"1438_CR9","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1038\/sj.bjc.6604367","volume":"98","author":"I Contreras-Hern\u00e1ndez","year":"2008","unstructured":"Contreras-Hern\u00e1ndez I, Mould-Quevedo JF, Silva A, Salinas-Escudero G, Villas\u00eds-Keever MA, Granados-Garc\u00eda V, et al. A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours. Br J Cancer. 2008;98:1762\u20138. https:\/\/doi.org\/10.1038\/sj.bjc.6604367.","journal-title":"Br J Cancer"},{"key":"1438_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-023-09850-2","author":"A Ruiz-Garcia","year":"2023","unstructured":"Ruiz-Garcia A, Baverel P, Bottino D, Dolton M, Feng Y, Gonz\u00e1lez-Garc\u00eda I, et al. A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development. J Pharmacokinet Pharmacodyn. 2023. https:\/\/doi.org\/10.1007\/s10928-023-09850-2.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1438_CR11","doi-asserted-by":"crossref","unstructured":"Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health. 2012;15:835\u201342. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1098301512016592.","DOI":"10.1016\/j.jval.2012.04.014"},{"key":"1438_CR12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40273-016-0381-4","volume":"34","author":"S Ghabri","year":"2016","unstructured":"Ghabri S, Hamers FF, Josselin JM. Exploring uncertainty in economic evaluations of drugs and medical devices: lessons from the first review of manufacturers\u2019 submissions to the French National Authority for Health. Pharmacoeconomics. 2016;34:617\u201324. https:\/\/doi.org\/10.1007\/s40273-016-0381-4.","journal-title":"Pharmacoeconomics"},{"key":"1438_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1137\/120889563","volume":"2","author":"M Strong","year":"2014","unstructured":"Strong M, Oakley JE. When is a model good enough? Deriving the expected value of model improvement via specifying internal model discrepancies. SIAM\/ASA J Uncertain Quantif. 2014;2:106\u201325. https:\/\/doi.org\/10.1137\/120889563.","journal-title":"SIAM\/ASA J Uncertain Quantif."},{"key":"1438_CR14","unstructured":"National Institute for Health and Care Excellence. (n.d.). NICE technology appraisal guidance. https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/nice-technology-appraisal-guidance. Accessed 30 July 2024."},{"key":"1438_CR15","unstructured":"ISPOR. (n.d.). Structured expert elicitation for healthcare decision making. Retrieved July 30, 2024, from https:\/\/www.ispor.org\/member-groups\/task-forces\/structured-expert-elicitation-for-healthcare-decision-making. Accessed 30 July 2024."},{"key":"1438_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development\u2014part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometr Syst Pharmacol. 2013;2:38. https:\/\/doi.org\/10.1038\/psp.2013.14.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"1438_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.71","volume":"3","author":"RN Upton","year":"2014","unstructured":"Upton RN, Mould DR. Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods. CPT Pharmacometr Syst Pharmacol. 2014;3: e88.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"1438_CR18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3389\/fphar.2020.00316","volume":"11","author":"M Centanni","year":"2020","unstructured":"Centanni M, Friberg LE. Model-based biomarker selection for dose individualization of tyrosine-kinase inhibitors. Front Pharmacol. 2020;11:316.","journal-title":"Front Pharmacol"},{"key":"1438_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/cpt.2051","volume":"110","author":"D Hill-McManus","year":"2021","unstructured":"Hill-McManus D, Marshall S, Liu J, Willke RJ, Hughes DA. Linked pharmacometric-pharmacoeconomic modeling and simulation in clinical drug development. Clin Pharmacol Ther. 2021;110:49\u201363. https:\/\/doi.org\/10.1002\/cpt.2051.","journal-title":"Clin Pharmacol Ther"},{"key":"1438_CR20","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40273-020-00944-0","volume":"38","author":"M Srinivasan","year":"2020","unstructured":"Srinivasan M, White A, Chaturvedula A, Vozmediano V, Schmidt S, Plouffe L, et al. Incorporating pharmacometrics into pharmacoeconomic models: applications from drug development. Pharmacoeconomics. 2020;38:1031\u201342.","journal-title":"Pharmacoeconomics"},{"key":"1438_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103477","volume":"9","author":"EL Giraud","year":"2024","unstructured":"Giraud EL, Westerdijk K, van der Kleij MBA, Guchelaar NAD, Meertens M, Bleckman RF, et al. Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes. ESMO Open. 2024;9: 103477.","journal-title":"ESMO Open."},{"key":"1438_CR22","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1158\/1078-0432.CCR-20-0887","volume":"26","author":"M Centanni","year":"2020","unstructured":"Centanni M, Krishnan SM, Friberg LE. Model-based dose individualization of sunitinib in gastrointestinal stromal tumors. Clin Cancer Res. 2020;26:4590\u20138.","journal-title":"Clin Cancer Res"},{"key":"1438_CR23","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2165\/11591540-000000000-00000","volume":"30","author":"J Pink","year":"2012","unstructured":"Pink J, Lane S, Hughes DA. Mechanism-based approach to the economic evaluation of pharmaceuticals. Pharmacoeconomics. 2012;30:413\u201329. https:\/\/doi.org\/10.2165\/11591540-000000000-00000.","journal-title":"Pharmacoeconomics"},{"key":"1438_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.62","volume":"2","author":"EK Hansson","year":"2013","unstructured":"Hansson EK, Ma G, Amantea MA, French J, Milligan PA, Friberg LE, et al. PKPD modeling of predictors for adverse effects and overall survival in sunitinib-treated patients with GIST. CPT Pharmacometr Syst Pharmacol. 2013;2: e85.","journal-title":"CPT Pharmacometr Syst Pharmacol."},{"key":"1438_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/psp.2013.61","volume":"2","author":"EK Hansson","year":"2013","unstructured":"Hansson EK, Amantea MA, Westwood P, Milligan PA, Houk BE, French J, et al. PKPD modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as predictors of tumor dynamics and overall survival following sunitinib treatment in GIST. CPT Pharmacometr Syst Pharmacol. 2013;2:84.","journal-title":"CPT Pharmacometr Syst Pharmacol."},{"key":"1438_CR26","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1002\/sim.8086","volume":"38","author":"TP Morris","year":"2019","unstructured":"Morris TP, White IR, Crowther MJ. Using simulation studies to evaluate statistical methods. Stat Med. 2019;38:2074\u2013102. https:\/\/doi.org\/10.1002\/sim.8086.","journal-title":"Stat Med"},{"key":"1438_CR27","unstructured":"Pfizer Medical Information. (n.d.). SUTENT (sunitinib malate)\u2014dosage and administration. https:\/\/www.pfizermedicalinformation.com\/sutent\/dosage-admin. Accessed 31 July 2024."},{"key":"1438_CR28","unstructured":"EuroQol Research Foundation. (n.d.). EQ-5D instruments. https:\/\/euroqol.org\/eq-5d-instruments\/. Accessed 30 July 2024."},{"key":"1438_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40273-017-0551-z","volume":"35","author":"R Ara","year":"2017","unstructured":"Ara R, Brazier J. Estimating health state utility values for comorbidities. Pharmacoeconomics. 2017;35:89\u201394. https:\/\/doi.org\/10.1007\/s40273-017-0551-z.","journal-title":"Pharmacoeconomics"},{"key":"1438_CR30","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1186\/s12885-022-10379-9","volume":"22","author":"P Sch\u00f6ffski","year":"2022","unstructured":"Sch\u00f6ffski P, George S, Heinrich MC, Zalcberg JR, Bauer S, Gelderblom H, et al. Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial. BMC Cancer. 2022;22:1302. https:\/\/doi.org\/10.1186\/s12885-022-10379-9.","journal-title":"BMC Cancer"},{"key":"1438_CR31","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s12094-008-0297-3","volume":"10","author":"L Paz-Ares","year":"2008","unstructured":"Paz-Ares L, del Muro XG, Grande E, Gonz\u00e1lez P, Brosa M, D\u00edaz S. Cost-effectiveness analysis of sunitinib in patients with metastatic and\/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib. Clin Transl Oncol. 2008;10:831\u20139. https:\/\/doi.org\/10.1007\/s12094-008-0297-3.","journal-title":"Clin Transl Oncol"},{"key":"1438_CR32","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3111\/13696998.2016.1151431","volume":"19","author":"C Beauchemin","year":"2016","unstructured":"Beauchemin C, Letarte N, Mathurin K, Yelle L, Lachaine J. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada. J Med Econ. 2016;19:619\u201329. https:\/\/doi.org\/10.3111\/13696998.2016.1151431.","journal-title":"J Med Econ"},{"key":"1438_CR33","doi-asserted-by":"publisher","first-page":"306","DOI":"10.25122\/jml-2018-0069","volume":"11","author":"A Liviu Preda","year":"2018","unstructured":"Liviu Preda A, Galieta MD. Cost-effectiveness analysis of treatment for metastatic renal carcinoma in Romania. J Med Life. 2018;11:306\u201311.","journal-title":"J Med Life"},{"key":"1438_CR34","unstructured":"Medicijnkosten 2024, Dutch National Health Care Institute. https:\/\/www.medicijnkosten.nl. Accessed 15 June 2024."},{"key":"1438_CR35","unstructured":"NZa. (n.d.). Nederlandse Zorgautoriteit (Dutch Healthcare Authority). https:\/\/www.nza.nl\/english. Accessed 30 July 2024."},{"key":"1438_CR36","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1111\/bcp.13990","volume":"85","author":"S Zuidema","year":"2019","unstructured":"Zuidema S, Desar IME, van Erp NP, Kievit W. Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: a cost-effectiveness study. Br J Clin Pharmacol. 2019;85:1994\u20132001.","journal-title":"Br J Clin Pharmacol"},{"key":"1438_CR37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/sj.bjc.6605417","volume":"102","author":"G Mickisch","year":"2010","unstructured":"Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-\u03b12a compared with sunitinib. Br J Cancer. 2010;102:80\u20136. https:\/\/doi.org\/10.1038\/sj.bjc.6605417.","journal-title":"Br J Cancer"},{"key":"1438_CR38","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s40273-016-0431-y","volume":"34","author":"M Versteegh","year":"2016","unstructured":"Versteegh M, Knies S, Brouwer W. From good to better: new dutch guidelines for economic evaluations in healthcare. Pharmacoeconomics. 2016;34:1071\u20134. https:\/\/doi.org\/10.1007\/s40273-016-0431-y.","journal-title":"Pharmacoeconomics"},{"key":"1438_CR39","doi-asserted-by":"publisher","first-page":"1849984","DOI":"10.1080\/20016689.2020.1849984","volume":"9","author":"S van der Schans","year":"2021","unstructured":"van der Schans S, Vondeling GT, Cao Q, van der Pol S, Visser S, Postma MJ, et al. The impact of patent expiry on drug prices: insights from the Dutch market. J Mark Access Health Policy. 2021;9:1849984. https:\/\/doi.org\/10.1080\/20016689.2020.1849984.","journal-title":"J Mark Access Health Policy."},{"key":"1438_CR40","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/cpt.787","volume":"102","author":"RB Verheijen","year":"2017","unstructured":"Verheijen RB, Yu H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR. Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther. 2017;102:765\u201376.","journal-title":"Clin Pharmacol Ther"},{"key":"1438_CR41","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/bcp.12550","volume":"79","author":"H Yu","year":"2015","unstructured":"Yu H, Steeghs N, Kloth JSL, de Wit D, van Hasselt JGC, van Erp NP, et al. Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. Br J Clin Pharmacol. 2015;79:809\u201319. https:\/\/doi.org\/10.1111\/bcp.12550.","journal-title":"Br J Clin Pharmacol"},{"key":"1438_CR42","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1038\/bjc.2014.194","volume":"110","author":"NAG Lankheet","year":"2014","unstructured":"Lankheet NAG, Kloth JSL, Gadellaa-van Hooijdonk CGM, Cirkel GA, Mathijssen RHJ, Lolkema MPJK, et al. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. Br J Cancer. 2014;110:2441\u20139.","journal-title":"Br J Cancer"},{"key":"1438_CR43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40273-013-0106-x","volume":"32","author":"GWJ Frederix","year":"2014","unstructured":"Frederix GWJ, van Hasselt JGC, Schellens JHM, H\u00f6vels AM, Raaijmakers JAM, Huitema ADR, et al. The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance. Pharmacoeconomics. 2014;32:47\u201361.","journal-title":"Pharmacoeconomics"},{"key":"1438_CR44","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/0272989X05281155","volume":"25","author":"LB Russell","year":"2005","unstructured":"Russell LB. Comparing model structures in cost-effectiveness analysis. Med Decis Mak. 2005;25:485\u20136. https:\/\/doi.org\/10.1177\/0272989X05281155.","journal-title":"Med Decis Mak"},{"key":"1438_CR45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/hec.1444","volume":"19","author":"LG Kim","year":"2010","unstructured":"Kim LG, Thompson SG. Uncertainty and validation of health economic decision models. Health Econ. 2010;19:43\u201355.","journal-title":"Health Econ"},{"key":"1438_CR46","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/j.1524-4733.2008.00502.x","volume":"12","author":"L Bojke","year":"2009","unstructured":"Bojke L, Claxton K, Sculpher M, Palmer S. Characterizing structural uncertainty in decision analytic models: a review and application of methods. Value Health J Int Soc Pharmacoecon Outcomes Res. 2009;12:739\u201349.","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res."},{"key":"1438_CR47","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1177\/0272989X11406986","volume":"31","author":"CH Jackson","year":"2011","unstructured":"Jackson CH, Bojke L, Thompson SG, Claxton K, Sharples LD. A framework for addressing structural uncertainty in decision models. Med Decis Mak. 2011;31:662\u201374. https:\/\/doi.org\/10.1177\/0272989X11406986.","journal-title":"Med Decis Mak"},{"key":"1438_CR48","unstructured":"Zorginstituut Nederland. (n.d.). SUTENT capsule 12.5mg. https:\/\/www.medicijnkosten.nl\/medicijn?artikel=SUTENT+CAPSULE+12%2C5MG&id=3f1f31593a46091a327290cff5b3a5a9. Accessed 30 July 2024."},{"key":"1438_CR49","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/bcp.14494","volume":"87","author":"DT Vithanachchi","year":"2021","unstructured":"Vithanachchi DT, Maujean A, Downes MJ, Scuffham P. A comprehensive review of economic evaluations of therapeutic drug monitoring interventions for cancer treatments. Br J Clin Pharmacol. 2021;87:271\u201383. https:\/\/doi.org\/10.1111\/bcp.14494.","journal-title":"Br J Clin Pharmacol"},{"key":"1438_CR50","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s10637-009-9306-9","volume":"28","author":"K Shirao","year":"2010","unstructured":"Shirao K, Nishida T, Doi T, Komatsu Y, Muro K, Li Y, et al. Phase I\/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs. 2010;28:866\u201375.","journal-title":"Invest New Drugs"},{"key":"1438_CR51","doi-asserted-by":"publisher","first-page":"9011","DOI":"10.1200\/jco.2005.23.16_suppl.9011","volume":"23","author":"RG Maki","year":"2005","unstructured":"Maki RG, Fletcher JA, Heinrich MC, Morgan JA, George S, Desai J, et al. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol. 2005;23:9011.","journal-title":"J Clin Oncol"},{"key":"1438_CR52","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","volume":"45","author":"S George","year":"2009","unstructured":"George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009;45:1959\u201368.","journal-title":"Eur J Cancer"},{"key":"1438_CR53","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (London, England). 2006;368:1329\u201338.","journal-title":"Lancet (London, England)."},{"key":"1438_CR54","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10928-017-9550-0","volume":"44","author":"Y Aoki","year":"2017","unstructured":"Aoki Y, R\u00f6shammar D, Hamr\u00e9n B, Hooker AC. Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection. J Pharmacokinet Pharmacodyn. 2017;44:581\u201397. https:\/\/doi.org\/10.1007\/s10928-017-9550-0.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1438_CR55","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","volume":"17","author":"AH Briggs","year":"2000","unstructured":"Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479\u2013500. https:\/\/doi.org\/10.2165\/00019053-200017050-00006.","journal-title":"Pharmacoeconomics"},{"key":"1438_CR56","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/hec.766","volume":"12","author":"A Briggs","year":"2003","unstructured":"Briggs A, Clark T, Wolstenholme J, Clarke P. Missing\u2026 presumed at random: cost-analysis of incomplete data. Health Econ. 2003;12:377\u201392.","journal-title":"Health Econ"},{"key":"1438_CR57","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40273-018-0650-5","volume":"36","author":"B Leurent","year":"2018","unstructured":"Leurent B, Gomes M, Faria R, Morris S, Grieve R, Carpenter JR. Sensitivity analysis for not-at-random missing data in trial-based cost-effectiveness analysis: a tutorial. Pharmacoeconomics. 2018;36:889\u2013901. https:\/\/doi.org\/10.1007\/s40273-018-0650-5.","journal-title":"Pharmacoeconomics"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01438-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-024-01438-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01438-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T14:08:28Z","timestamp":1736604508000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-024-01438-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1438"],"URL":"https:\/\/doi.org\/10.1007\/s40273-024-01438-z","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]},"assertion":[{"value":"15 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Uppsala University. This research was funded by the Swedish Cancer Society (CAN 20 1226 PjF, 23 2921 Pj). The computations were enabled by resources provided by the Swedish National Infrastructure for Computing (SNIC) and National Academic Infrastructure for Super\u00adcomputing in Sweden (NAISS) at Uppsala University partially funded by the Swedish Research Council through grant agreement no. 2022-06725 and no. 2018-05973.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data that support the findings of this study are not openly accessible, but can be made available from the authors upon reasonable request from the corresponding author L.E.F.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The code that support the findings of this study are not openly accessible, but can be made available from the authors upon reasonable request from the corresponding author L.E.F.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"M.C, J.N. L.E.F., and M.O.K. wrote the manuscript; M.C., L.E.F., and M.O.K. designed the research and analyzed the data; M.C. and J.N. performed the research.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}